Ischemic stroke is a significant global health challenge that leads to substantial neurological impairments and mortality. This study introduces an innovative biomarker for early, sensitive detection of ischemic brain injury, circumventing the limitations of traditional imaging. This biomarker, which is involved in key biological processes, such as protease inhibition and neuroinflammation, has shown a unique pattern of response under ischemic conditions. Our investigations revealed marked alterations in its levels, with pronounced changes in secretion and expression during the critical phases of hypoxia-reoxygenation. The early phases of hypoxia were particularly notable for the surge in specific biomarker fragments, illustrating the biomarker\'s sensitivity to ischemic events through dynamic changes in its profile. Further validation in a rodent model of cerebral ischemia underscored the significant alterations in the biomarker, affirming its critical role in the body\'s response to ischemic injury. Our findings introduce this biomarker as a groundbreaking tool for ischemic stroke early detection, offering insights into stroke pathophysiology and cognitive decline, and paving the way for improved diagnostic and therapeutic approaches. The biomarker\'s dynamic response to ischemic conditions holds promise for enhancing stroke diagnosis and facilitating timely interventions, potentially mitigating neurological damage progression.